Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Perrigo Company plc PRGO

Healthcare
Perrigo Company plc is an Ireland-based provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. The Company's segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises its consumer self-care business (OTC, infant formula, and oral care categories, and contract... see more

Recent & Breaking News (NYSE:PRGO)

Perrigo Reports Third Quarter Fiscal Year 2022 Financial Results From Continuing Operations

PR Newswire November 8, 2022

Perrigo Announces Quarterly Dividend

PR Newswire November 3, 2022

Perrigo Announces Strategic Investment to Expand and Strengthen U.S. Manufacturing of Infant Formula

PR Newswire November 1, 2022

Perrigo Receives Notification of Postponement for Joint FDA Advisory Committee to Review Opill® Daily Oral Contraceptive for Over-The-Counter (OTC) Use

PR Newswire October 26, 2022

Perrigo to Release Third Quarter 2022 Financial Results on November 8, 2022

PR Newswire October 25, 2022

PERRIGO ANNOUNCES JOINT FDA ADVISORY COMMITTEE TO REVIEW OPILL® DAILY ORAL CONTRACEPTIVE FOR OVER-THE-COUNTER (OTC) USE

PR Newswire September 12, 2022

PERRIGO RELEASES STATEMENT ON RECENT MARKET TRADING ACTIVITY

PR Newswire August 17, 2022

PERRIGO REPORTS SECOND QUARTER FISCAL YEAR 2022 FINANCIAL RESULTS FROM CONTINUING OPERATIONS

PR Newswire August 9, 2022

PERRIGO ANNOUNCES QUARTERLY DIVIDEND

PR Newswire August 2, 2022

PERRIGO TO RELEASE SECOND QUARTER 2022 FINANCIAL RESULTS ON AUGUST 9, 2022

PR Newswire July 27, 2022

Perrigo's HRA Pharma Submits Application to FDA for First-Ever OTC Birth Control Pill

PR Newswire July 11, 2022

PERRIGO PROMOTES ALISON IVES TO ROLE OF CHIEF SCIENTIFIC OFFICER

PR Newswire June 1, 2022

PERRIGO ANNOUNCES U.S. FDA APPROVAL FOR OMEPRAZOLE MAGNESIUM DELAYED-RELEASE MINI CAPSULES

PR Newswire May 26, 2022

PERRIGO TO PRESENT AT UPCOMING CONSUMER INVESTOR CONFERENCES

PR Newswire May 19, 2022

PERRIGO REPORTS FIRST QUARTER FISCAL YEAR 2022 FINANCIAL RESULTS FROM CONTINUING OPERATIONS, RAISES GUIDANCE

PR Newswire May 11, 2022

PERRIGO ANNOUNCES PLANNED LEADERSHIP SUCCESSION

PR Newswire May 11, 2022

PERRIGO ANNOUNCES QUARTERLY DIVIDEND

PR Newswire May 5, 2022

PERRIGO COMPLETES THE ACQUISITION OF HRA PHARMA

PR Newswire May 2, 2022

PERRIGO ANNOUNCES EXPECTED TRANSACTION CLOSE DATE OF HRA PHARMA

PR Newswire April 28, 2022

PERRIGO TO RELEASE FIRST QUARTER 2022 FINANCIAL RESULTS ON MAY 11, 2022

PR Newswire April 27, 2022